Author/Authors :
Sheikhpour, Mojgan Department of Mycobacteriology and Pulmonary Research - Pasteur Institute of Iran, Tehran, Iran , Sadeghizadeh, Majid Department of Genetic - Faculty of Biological Sciences Tarbiat Modares University, Tehran, Iran , Yazdian, Fatemeh Department of Life Science Engineering - Faculty of New Sciences and Technologies University of Tehran, Tehran, Iran , Mansoori, Ali Department of Life Science Engineering - Faculty of New Sciences and Technologies University of Tehran, Tehran, Iran , Asadi, Hassan Department of Mycobacteriology and Pulmonary Research - Pasteur Institute of Iran, Tehran, Iran , Movafagh, Abolfazl Department of Medical Genetics - Cancer Research Center - Shohada Hospital School of Medicine - Shahid Beheshti University of Medical Science, Tehran, Iran , Shahraeini, Sadegh Department of Mycobacteriology and Pulmonary Research - Pasteur Institute of Iran, Tehran, Iran
Abstract :
In recent years, nanotechnology with modern advances in the macromolecular design of nano-carriers has proved to be helpful in the development of drugs delivery systems. This research represents a novel co-administration of nano-vehicles, known as liposomes. Liposomes efficiently encapsulate curcumin and bromocriptine (BR) in a polymer structure, which results in enhanced aqueous solubility of the mentioned hydrophobic agents and higher bioavailability of the drugs. Methods: Preparation of curcumin and BR liposomes were carried out by the thin film method, and the amounts of purified drug and its release were analyzed. After dose determination, the human lung cancer cells (QU-DB) were exposed to BR and curcumin liposomes for 12, 24, and 48 h. Then the viability and apoptosis assays were carried out by using tetrazolium dye and flow cytometry technique, respectively. Results: In this research, in vitro anti-cancer effects of former nano-formulations on lung cancer cells was confirmed, and no cytotoxicity effects of these nano-preparations were observed in the normal cells (HFLF-PI5). Conclusion: Our findings suggest the nano-liposomal drugs as effective anti-cancer agents; however, additional clinical examinations are required.
